Cardinal Health, Inc.
Compare market positioning with top industry peers
Explore Cardinal Health
Core profile pages, annual revenue records, and related research hubs for this company.
Leadership History
5 leaders · 1971 to present
This is not a paradox: the OptumRx contract was generating below-average margins, and its departure actually improved Cardinal Health's overall profitability profile. The volume is enormous. These specialty platforms serve physician practices directly, bypassing the commodity dynamics of wholesale distribution. It is a small fraction of total revenue and an outsized fraction of strategic value. The pivot was well-timed. The U.S. Pharmaceutical market was beginning a structural expansion driven by demographic aging and pharmaceutical innovation that would continue for decades. Walter spent the 1980s and 1990s systematically acquiring pharmaceutical distributors across the country, consolidating a fragmented industry into an oligopoly. The opioid crisis left a significant mark. The reputational and financial costs were substantial. In 1979, he made the pivot, acquiring Ellicott Drug and beginning the transformation into a pharmaceutical company.
CEO
2022 – Present
4 years (current)
Hollar became CEO in September 2022 and has led Cardinal Health through the OptumRx contract loss, the specialty care acquisition strategy (ION, GI Alliance, ADSG, Solaris Health), and the fiscal 2026 guidance raise. He has focused on diversifying revenue sources, improving profitability, and building higher-margin healthcare services businesses.
CEO
2018 – 2022
4 years
Kaufmann led Cardinal Health through the opioid litigation settlement and the COVID-19 pandemic, which created unprecedented demand for medical supplies and pharmaceuticals. He focused on operational execution and maintaining supply chain continuity during the crisis.
Chairman and CEO
2009 – 2017
8 years
Barrett led Cardinal Health through significant strategic initiatives including the acquisition of the Patient Recovery business from Medtronic ($6.1 billion) and the establishment of the Red Oak Sourcing joint venture with CVS Health. He navigated the company through the Walgreens contract loss and early opioid litigation.
Chairman and CEO
2006 – 2009
3 years
Clark led Cardinal Health through a period of strategic repositioning, including the spin-off of the CareFusion medical technology business. He focused on improving operational efficiency and addressing the challenges of the post-Walter era.
Founder, Chairman, and CEO
1971 – 2004
33 years
Walter founded Cardinal Health in 1971 as a food wholesaler and pivoted to pharmaceutical distribution in 1979. He executed dozens of acquisitions that transformed the company from a small regional distributor into a $50+ billion healthcare conglomerate. His decentralized management philosophy and acquisition discipline shaped Cardinal Health's corporate culture. He served as CEO for 33 years.
But the path is not without risk: integration of acquired physician practices, reimbursement pressure from Medicare and commercial payers, and the ever-present threat of further customer concentration changes (CVS Health remains a significant revenue source) could derail the transformation. The competitive threat from vertical integration by customers is a persistent concern. While these efforts have not significantly reshaped the wholesale oligopoly, they represent a long-term competitive threat that could erode distributor margins. The OptumRx contract loss, while partially absorbed, exposed the vulnerability of customer concentration in a business where single contracts can represent double-digit percentages of revenue. The concentration risk extends beyond OptumRx: CVS Health remains a major customer through both direct distribution and the Red Oak Sourcing joint venture, and any deterioration in this relationship would have severe consequences. The pharmaceutical supply chain is subject to extensive federal and state regulation, including the Drug Supply Chain Security Act (DSCSA), which requires track-and-trace capabilities for prescription drugs. The Global Medical Products and Distribution segment faces its own challenges. The acquisition integration risk is substantial. Yet finally, the strategic challenge of margin expansion in a structurally low-margin business is existential. The manufacturing capabilities in the Global Medical Products and Distribution segment, while challenged by competition, provide vertical integration that pure distributors lack. The macroeconomic environment presents both opportunities and risks. His brief stint as an engineer at North American Rockwell (later Rockwell International) had been formative in a negative way: Walter loathed the company's bureaucratic culture, rigid seniority system, and risk-averse mindset. The 2010s also brought challenges. The loss of Walgreens revenue, while partially offset by new business, demonstrated the customer concentration risk that would resurface with the OptumRx loss a decade later.
Jason Hollar currently leads Cardinal Health, Inc., overseeing strategic vision, balance sheet health, and organizational execution in Healthcare Distribution / Medical Distribution.
Under executive direction, Cardinal Health, Inc. is prioritizing workflow automation alongside disciplined capital allocation to maximize shareholder value.
Leadership at Cardinal Health, Inc. has historically navigated industry cycles by restructuring operational priorities and expanding competitive moats.